Avantor, Inc. (NYSE:AVTR – Get Free Report) Director Sanjeev Mehra acquired 125,000 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average cost of $8.01 per share, for a total transaction of $1,001,250.00. Following the transaction, the director owned 475,000 shares in the company, valued at approximately $3,804,750. The trade was a 35.71% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Avantor Stock Up 2.1%
Shares of NYSE AVTR traded up $0.17 during trading hours on Wednesday, hitting $8.32. 9,661,164 shares of the stock were exchanged, compared to its average volume of 12,524,850. Avantor, Inc. has a 12 month low of $7.82 and a 12 month high of $17.11. The firm has a fifty day moving average price of $10.57 and a 200-day moving average price of $11.77. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company has a market cap of $5.68 billion, a PE ratio of -10.67, a PEG ratio of 3.20 and a beta of 0.97.
Avantor (NYSE:AVTR – Get Free Report) last announced its earnings results on Wednesday, February 11th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.01. Avantor had a negative net margin of 8.09% and a positive return on equity of 10.45%. The company had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same period last year, the firm earned $0.27 earnings per share. Avantor’s revenue was down 1.4% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.770-0.830 EPS. On average, sell-side analysts expect that Avantor, Inc. will post 1.06 EPS for the current year.
Hedge Funds Weigh In On Avantor
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on AVTR. Barclays reissued an “underweight” rating and issued a $8.50 price objective on shares of Avantor in a research report on Friday, March 6th. TD Cowen reiterated a “hold” rating on shares of Avantor in a research note on Thursday, February 12th. Citigroup lowered their price target on Avantor from $13.00 to $11.00 and set a “neutral” rating for the company in a report on Thursday, February 12th. Wells Fargo & Company dropped their price target on Avantor from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Finally, Robert W. Baird set a $11.00 price objective on shares of Avantor in a report on Thursday, February 12th. Three research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $11.80.
View Our Latest Analysis on AVTR
Avantor Company Profile
Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor’s offerings are organized across two primary segments.
Recommended Stories
- Five stocks we like better than Avantor
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
